Kura Oncology reported a net loss of $57.4 million for the first quarter of 2025, compared to a net loss of $49.5 million for the same period in 2024. The company's collaboration revenue significantly increased to $14.1 million from no revenue in the prior year, driven by its partnership with Kyowa Kirin. Research and development expenses rose to $56.0 million, reflecting increased clinical activities. The company ended the quarter with $658.2 million in cash, cash equivalents, and short-term investments, with a pro forma cash of $703.2 million after accounting for a $45 million milestone payment.
NDA for ziftomenib submitted to FDA in Q1 2025 for relapsed or refractory AML with NPM1 mutation, triggering a $45 million milestone payment from Kyowa Kirin.
Positive topline results from KOMET-001 (ziftomenib in R/R NPM1-m AML) accepted for oral presentation at ASCO and EHA.
First patients dosed in KOMET-015 trial evaluating ziftomenib plus imatinib in advanced GIST after imatinib failure.
Pro forma cash, cash equivalents, and short-term investments of $703.2 million as of March 31, 2025, expected to fund operations into 2027 and support ziftomenib commercialization.
Kura Oncology anticipates several key milestones in 2025, including further clinical data presentations, initiation of Phase 3 trials for ziftomenib, and advancement of its other pipeline programs, supported by its strong financial position.
Analyze how earnings announcements historically affect stock price performance